A Phase 2 interventional study of B244 and Vehicle in Rosacea, sponsored by AOBiome LLC. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-16.
Sponsored by AOBiome LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.
Among the 145 studies in Rosacea with a site in United States, this one is the 54th largest by enrollment of the 137 interventional ones that give a count, is one of 8 that started in 2018, is one of 35 in phase 2, and was the 103rd registered.
233 studies on the registry are indexed under Rosacea; 23 are open to participants now.
Browse Rosacea studies →8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Narrows Institute for Biomedical Research · Sites in United States
Ages 18+ · Healthy volunteers
University of Miami · Sites in United States
Ages 18+
Wright State University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 44 · Phase 3 34 · Phase 4 20
First in 2002; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 78 across the 137 interventional studies, 236 across the 8 observational. Of the 127 that completed or were terminated, 76 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 145 have an industry lead sponsor. The 10 most frequent:
AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AOBiome LLC has 1 study filed under Rosacea — fewer than ten, so there is no comparison to draw.
3 of the studies in Rosacea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07443202Tarsus Pharmaceuticals, Inc.Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | 2026-12-31 |
| NCT06801717University of MiamiRosacea Radiofrequency Microneedling | 2027-07-01 |
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 145 studies in Rosacea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.
At Screening and Baseline all subjects must have Type 1 erythematotelangiectatic rosacea (ETR).
The total duration of the study will be approximately 12 weeks. Participants will report for a Screening visit and if all inclusion criteria are met will undergo a washout period, between 2 days and 4 weeks, depending on current treatment. Subjects will then report for the Baseline visit.
Subjects will come in for visits at Day 7 (Week 1), Day 28 (Week 4), and Day 56 (Week 8). A final visit will be conducted at Day 84 (Week 12).
Efficacy will be assessed using Clinician Erythema Assessment (CEA), Investigator Global Assessment (IGA), Skindex16, and Patient Self-Assessment (PSA).
Blood and urine samples will be collected for standard safety laboratory tests. Participant's safety will be monitored throughout the study.
Investigators plan to enroll approximately 130 subjects.
Randomization will be 1:1 so that equal numbers of subjects will be treated in each arm of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B244 suspension in 30ml/bottle Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day.
Biological: B244
Vehicle, 30ml/bottle Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day.
Biological: Vehicle
B244 Suspension
Vehicle suspension
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Safety and tolerability endpoints will consist of all treatment-related adverse events reporting during the study duration.
Time frame: Baseline to Day 84
Proportion of Subjects With IGA Improvement at Week 8 Relative to Baseline.
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). Improvement is defined as at least 1-grade change.
Time frame: Baseline to Day 56
Proportion of Subjects With CEA Improvement at Week 8 Relative to Baseline.
Clinical Erythema Assessment (CEA) was used to assess the extent of rosacea on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). Improvement is defined as at least 1-grade change.
Time frame: Baseline to Day 56
Change in IGA From Week 8 to Baseline.
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). A higher grade change indicates greater improvement in disease.
Time frame: Baseline to Day 56
Change in CEA From Week 8 to Baseline.
Clinical Erythema Assessment (CEA) was used to assess the extent of rosacea on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). A higher grade change indicates greater improvement in disease.
Time frame: Baseline to Day 56
Change in Skindex 16 and Skindex 16 Sub Scores at Week 1, Week 4, Week 8 and Week 12 From Baseline.
The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.
Time frame: Baseline to Day 84
Proportion of Subjects With Change in PSA at Week 1, Week 4, Week 8 and Week 12 From Baseline.
Subjects were asked to perform static ("snap-shot") evaluations of their rosacea-associated facial erythema severity using the Patient Self Assessment scale (PSA) at each study visit, and report the one integer that best describes the overall severity of their facial redness as seen in a mirror at the time of the evaluation on a scale of 0 to 4 (0=no redness, 1=very mild redness, 2=mild redness, 3=moderate redness, 4=severe redness). A higher grade change indicates greater improvement.
Time frame: Baseline to Day 84
| Milestone | B244 | Vehicle |
|---|---|---|
| Started | 73 | 67 |
| Completed | 70 | 59 |
| Not completed | 3 | 8 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 |
Safety and tolerability endpoints will consist of all treatment-related adverse events reporting during the study duration.
| Participants | B244 | Vehicle |
|---|---|---|
| Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | 5 | 6 |
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). Improvement is defined as at least 1-grade change.
| Participants | B244 | Vehicle |
|---|---|---|
| Proportion of Subjects With IGA Improvement at Week 8 Relative to Baseline. | 51 | 38 |
Clinical Erythema Assessment (CEA) was used to assess the extent of rosacea on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). Improvement is defined as at least 1-grade change.
| Participants | B244 | Vehicle |
|---|---|---|
| Proportion of Subjects With CEA Improvement at Week 8 Relative to Baseline. | 49 | 38 |
IGA (Investigator's Global Assessment) was used to assess the overall diseases severity on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild disease, 3=moderate disease, and 4=severe disease). A higher grade change indicates greater improvement in disease.
| Participants | B244 | Vehicle |
|---|---|---|
| Week 8 1-Grade Change | 34 | 26 |
| Week 8 2-Grade Change | 14 | 10 |
| Week 8 3-Grade Change | 3 | 2 |
Clinical Erythema Assessment (CEA) was used to assess the extent of rosacea on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe). A higher grade change indicates greater improvement in disease.
| Participants | B244 | Vehicle |
|---|---|---|
| Week 8 1-Grade Change | 34 | 27 |
| Week 8 2-Grade Change | 14 | 10 |
| Week 8 3-Grade Change | 1 | 1 |
The Skindex 16 questionnaire was assigned to subjects to examine the relationship between the subject's skin health and quality of life. Subjects scored 16 questions from 0 to 6 (0=never bothered, 6=always bothered). Total scores could range between 0 to 96, where a higher score is associated with a worse quality of life.
| score on a scale | B244 | Vehicle |
|---|---|---|
| Change from Baseline at Week 1 | -8.7 ± 12.584 | -12.4 ± 17.111 |
| Change from Baseline at Week 4 | -14.5 ± 13.908 | -18.4 ± 17.418 |
| Change from Baseline at Week 8 | -21.0 ± 20.878 | -19.9 ± 20.164 |
| Change from Baseline at Week 12 (EOS) | -19.7 ± 22.152 | -20.6 ± 22.694 |
Subjects were asked to perform static ("snap-shot") evaluations of their rosacea-associated facial erythema severity using the Patient Self Assessment scale (PSA) at each study visit, and report the one integer that best describes the overall severity of their facial redness as seen in a mirror at the time of the evaluation on a scale of 0 to 4 (0=no redness, 1=very mild redness, 2=mild redness, 3=moderate redness, 4=severe redness). A higher grade change indicates greater improvement.
| Participants | B244 | Vehicle |
|---|---|---|
| Week 1 — 0-Grade Change | 49 | 44 |
| Week 1 — 1-Grade Change | 19 | 19 |
| Week 1 — 2-Grade Change | 5 | 3 |
| Week 1 — 3-Grade Change | 0 | 0 |
| Week 4 — 0-Grade Change | 29 | 23 |
| Week 4 — 1-Grade Change | 36 | 30 |
| Week 4 — 2-Grade Change | 5 | 6 |
| Week 4 — 3-Grade Change | 1 | 0 |
| Week 8 — 0-Grade Change | 23 | 21 |
| Week 8 — 1-Grade Change | 31 | 24 |
| Week 8 — 2-Grade Change | 14 | 11 |
| Week 8 — 3-Grade Change | 3 | 3 |
| Week 12 (EOS) — 0-Grade Change | 23 | 22 |
| Week 12 (EOS) — 1-Grade Change | 29 | 21 |
| Week 12 (EOS) — 2-Grade Change | 15 | 14 |
| Week 12 (EOS) — 3-Grade Change | 3 | 2 |
Collected over Baseline to Week 12.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B244 | 0/73 (0%) | 0/73 (0%) | 19/73 (26%) |
| Vehicle | 0/67 (0%) | 0/67 (0%) | 12/67 (17.9%) |
| Event | B244 | Vehicle |
|---|---|---|
| Application site painGeneral disorders | 1/73 | 3/67 |
| PruritusSkin and subcutaneous tissue disorders | 3/73 | 0/67 |
| Application site drynessGeneral disorders | 1/73 | 2/67 |
| Application site pruritusGeneral disorders | 0/73 | 2/67 |
| HordeolumInfections and infestations | 2/73 | 0/67 |
| Urinary tract infectionInfections and infestations | 2/73 | 0/67 |
| RashSkin and subcutaneous tissue disorders | 2/73 | 1/67 |
| HeadacheNervous system disorders | 2/73 | 1/67 |
| Viral upper respiratory tract infectionInfections and infestations | 1/73 | 1/67 |
| Acute sinusitisInfections and infestations | 0/73 | 1/67 |
Modified Intent to Treat (mITT) Population: all subjects who all subjects who met all inclusion/exclusion criteria, were randomized, dispensed treatment, and had at least one post-treatment efficacy evaluation.
| Age, Continuous(years) | B244 | Vehicle | Total |
|---|---|---|---|
| Mean | 50.6 ± 15.099 | 52.4 ± 13.022 | 51.5 ± 14.120 |
| Sex: Female, Male(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| Female | 55 | 48 | 103 |
| Male | 18 | 19 | 37 |
| Ethnicity (NIH/OMB)(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 31 | 31 | 62 |
| Not Hispanic or Latino | 42 | 36 | 78 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | B244 | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 72 | 65 | 137 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Feb 2019, 7 months.
Results were first posted in Sep 2022, 3 years 7 months after primary completion. A results delay was requested in Jul 2020.
Of 20 phase 2 interventional studies under Rosacea, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC